Dianthus Therapeutics, Inc. (DNTH) community

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$91.81−0.67 (-0.72%)

Close on Nov 13, 2026Market cap $5.14BP/E –Yield 0.00%

Community

Notes and questions about Dianthus Therapeutics from other investors

No posts about DNTH yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Dianthus Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-67 reverse split on Nov 9, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNTH.

Compare: DNTH vs UPB · DNTH vs CNTB · DNTH vs RNAC · DNTH vs ACRS · DNTH vs YARW

Revenue growth-67.3% · median 0.2%

Operating margin-11592.7% · median -6116.0%

Net margin-9927.5% · median -5712.3%

Company	Revenue	Growth
ACRS	$6.40M	-59.3%
CNTB	$2.95M	+50.3%
UPB	$2.87M	+2.5%
DNTH	$2.04M	-67.3%
RNAC	$1.03M	–
YARW	$476.00K	-2.1%

Company

Next earnings (est.): Mar 8, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 92
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1690585

Advertisement
300 × 250

See a number that looks wrong?